THE API POWDER DIARIES

“The existing circumstance has exposed some structural weaknesses inside the EU’s medicines offer chain as well as a significant dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides said. She proposed that offer chain issues be tackled in an EU pharmaceutical approach envisioned to become introduced